Press releases

ORYZON to provide corporate progress updates at several events in May-June

ORYZON reports financial results and corporate update for quarter ended March 31, 2025

ORYZON awarded 13.26 million € through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project)

ORYZON Raises €30 Million in Capital Increase

ORYZON continues to strengthen its patent portfolio for vafidemstat

ORYZON announces first patient dosed in NCI-sponsored Phase I/II clinical trial of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer

ORYZON to provide corporate progress updates at several events in March-April

Oryzon announces publication of study on Phelan-McDermid Syndrome (PMS) patients, a form of autism, paving the way for a novel personalized medicine approach with vafidemstat

Oryzon defines Phase III Trial endpoints for Agitation and Aggression in BPD with input from new Clinical Advisory Board

ORYZON announces the voting results of February 2025 Extraordinary General Shareholders' Meeting